Stockholm III trial

Denna sida på svenska

The Stockholm III trial is a randomised, multicentre trial, comparing different radiationtherapy courses in primary resectable rectal cancer.

Patients are randomised between one of the following arms:

  1. Preoperative radiotherapy 5 x 5 Gy with surgery within one week
  2. Preoperative radiotherapy 5 x 5 Gy with surgery after 4-8 weeks
  3. Preoperative radiotherapy 25 x 2 Gy with surgery after 4-8 weeks

Inclusion criteria:

Primary resectable, biopsy proven adenocarcinoma of the rectum, without signs of distant metastases where abominal surgery is planned. 

Primary Investigator

Professor/senior physician

Anna Martling

Phone: +46-(0)8-517 728 02
Organizational unit: Colorectal Surgery
E-mail: Anna.Martling@ki.se

www.clinicaltrials.gov NCT00904813

Study protocol

Study protocol Stockholm III

Publikationer

Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.
Erlandsson J, Holm T, Pettersson D, et al
Lancet Oncol. 2017 Feb;18(3):336-46, Link to author's manuscript

Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer.
Pettersson D, Cedermark B, Holm T, Radu C, Påhlman L, Glimelius B, et al
Br J Surg 2010 Apr;97(4):580-7

Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial.
Pettersson D, Glimelius B, Iversen H, Johansson H, Holm T, Martling A
Br J Surg 2013 Jun;100(7):969-75

Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer.
Pettersson D, Lörinc E, Holm T, Iversen H, Cedermark B, Glimelius B, et al
Br J Surg 2015 Jul;102(8):972-8; discussion 978

Cancer and Oncology